Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.
Oncologist
December 2024
Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, People's Republic of China.
Background: Both novel anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) and pertuzumab and trastuzumab (HP) combined with chemotherapy(C) regimens are the choice of treatment for HER2 positive metastatic breast cancer (MBC) after tyrosine kinase inhibitors (TKIs). Our team's previous research has shown significant therapeutic effects of novel anti-HER2 ADCs in patients with TKIs treatment failure. Unfortunately, there is currently no data available to compare novel anti-HER2 ADCs with HP combined with chemotherapy regimens.
View Article and Find Full Text PDFNatural Hydrogel-based Drug Delivery System: A Global Scenario, Current Development, and Future Prospective.
Curr Drug Deliv
January 2025
Department of Pharmaceutics, Y. B. Chavan College of Pharmacy, Aurangabad, India.
Pharmaceutical giants (e.g., Ashland, Bausch & Lomb, Johnson & Johnson, Medtronic, Neurelis, etc.
View Article and Find Full Text PDFProvision of continuous renal replacement therapy in children in intensive care in Australia and New Zealand.
Crit Care Resusc
December 2024
Paediatric Critical Care Research Group, Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia.
Objectives: The objective of this study was to describe current use, clinical practice, and outcomes of continuous renal replacement therapy (CRRT) in children in the intensive care unit (ICU) in Australia and New Zealand.
Design: retrospective, binational registry-based cohort study and electronic survey of clinical practice.
Setting: ICUs that contribute to the Australian and New Zealand Paediatric Intensive Care Registry and a survey conducted in November 2021 including ICUs accredited for paediatric intensive care training that provide CRRT for children were part of this study.
Shear bond strength evaluation of bioactive restorative materials on pretreated carious dentin-influence on silver diamine fluoride, potassium iodide, and glutathione.
J Conserv Dent Endod
November 2024
Department of Conservative Dentistry and Endodontics, Subharti Dental College and Hospital, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India.
Background: Silver diamine fluoride (SDF) has gained popularity for its caries-arresting properties, yet its tendency to cause esthetic concerns due to black-staining limits its widespread acceptance.
Aim: The aim of the study was to evaluate and compare the shear bond strength of Activa BioActive and Giomer restorative material with different protocols of SDF pretreatment on carious dentin.
Materials And Methods: Ninety-two extracted teeth were decoronated at the cementoenamel junction, sectioned 1 mm into dentin, mounted in acrylic resin and randomly divided into four ( = 8) control and six ( = 10) experimental groups.
Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis.
Ther Adv Med Oncol
January 2025
Department of Oncology, Zhuzhou Second Hospital, Zhuzhou, Hunan 412000, China.
Background: Both the antibody-drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.
Objectives: To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!